Ivonescimab in Neoadjuvant NSCLC: Testing a PD-1/VEGF Bi-specific

Is this trial a fit for you?

A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.

What this trial studies

This observational study compares Ivonescimab with conventional PD-1 inhibitors when used as neoadjuvant therapy for NSCLC. It aims to explore not only efficacy and safety but also the mechanisms behind Ivonescimab’s potential enhanced effect. Secondary analyses include biomarker identification and multi-omics profiling to understand predictors of response and the drug’s molecular action in the tumor microenvironment. The work intends to support precision medicine strategies and rational clinical use of Ivonescimab in resectable NSCLC. The study is conducted at Peking University People’s Hospital in Beijing, China.

Why it matters

Who can join: the full rules

Inclusion Criteria:

Patients with non-small cell lung cancer (Stage IB-IIIB) who require radical surgery following neoadjuvant therapy.

Exclusion Criteria:

1. Histology of other malignant tumors, including concurrent malignant tumors of other organ systems;
2. Unresectable advanced disease (Stage IV) or locally advanced unresectable (Stage IIIC);
3. Pregnancy or lactation;
4. Insufficient sample quality;
5. Severe organ dysfunction (e.g. cardiac or renal insufficiency);
6. Other judgments by the Investigator that the patient should not participate in the study.

Where it's running

• Peking University People's Hospital
  Beijing, Beijing Municipality, China Recruiting

Study contacts

• Principal investigator: Fan Yang — Peking University People's Hospital
• Study coordinator: Hao Li
• Email: lihao_pkuhsc@163.com
• Phone: +86 13051713494

Similar studies

Other studies for the same condition or treatment. Recruiting studies are listed first.

• Neoadjuvant Cemiplimab + Dupilumab in Early-Stage NSCLC

  This study tests whether giving cemiplimab with dupilumab before surgery can be safe and help shrink tumors in people with early-stage non-small cell lung cancer.

  Recruiting Centre hospitalier de l'Université de Montréal (CHUM) · Montreal, Quebec and 1 other locations · NCT06743581

• MRD-guided postoperative monitoring and adaptive treatment for resectable NSCLC

  This study tests a personalized follow-up and treatment plan using ctDNA MRD testing and pathology to guide adjuvant therapy after surgery for stage IB-IIIA NSCLC treated with neoadjuvant immunotherapy.

  Recruiting Peking University People's Hospital · Beijing, Beijing Municipality · NCT07894458

• AK138D1 alone or with Ivonescimab in advanced non-small cell lung cancer

  This study tests AK138D1 by itself or with Ivonescimab in adults with advanced non-small cell lung cancer to see if it is safe and can help shrink tumors.

  Recruiting Phase 1/2 Akeso · Shanghai, Shanghai Municipality · NCT07623356

• Tepotinib plus Ivonescimab for MET exon 14–positive NSCLC

  This study tests whether a combination of tepotinib and ivonescimab is safe and helps people with MET exon 14–skipping non-small cell lung cancer.

  Recruiting at 7 sites Phase 1 Memorial Sloan Kettering Cancer Center · Basking Ridge, New Jersey and 6 other locations · NCT07619339

• Ivonescimab after SBRT for early-stage NSCLC

  This study tests whether adding ivonescimab after standard SBRT helps people with early-stage non-small cell lung cancer.

  Recruiting at 7 sites Phase 1/2 Memorial Sloan Kettering Cancer Center · Basking Ridge, New Jersey and 6 other locations · NCT07594522

• Ivonescimab with chemotherapy and stereotactic radiosurgery for NSCLC brain metastases

  This trial tests whether adding the experimental drug ivonescimab to standard chemotherapy and stereotactic radiosurgery helps people with non-small cell lung cancer that has spread to the brain.

  Recruiting at 7 sites Phase 1/2 Memorial Sloan Kettering Cancer Center · Basking Ridge, New Jersey and 6 other locations · NCT07535463

How to take part

1. Review the eligibility criteria above with your treating physician.
2. Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
3. Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.